American Laboratory Products Company (ALPCO) Merges with GeneProof

Ampersand Capital Partners Recapitalizes American Laboratory Products Company (ALPCO)

September 21, 2020

Medical Devices

Ampersand Capital Partners completed a majority recapitalization of American Laboratory Products Company (ALPCO) to provide growth capital for expanding ALPCO's diagnostics test kit offering, geographic reach, and R&D/production capabilities. Founders Richard and Jan Conley will remain shareholders, Sean Conley will continue as CEO, and Larry McCarthy, PhD was named Board Chairman.

Ginkgo Bioworks Acquires Proof Diagnostics

February 28, 2024

Biotechnology

Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.

Ampersand Capital Partners Majority Recapitalizes Leinco Technologies

November 10, 2021

Biotechnology

Ampersand Capital Partners has completed a majority recapitalization of Leinco Technologies, a specialty manufacturer of life-science reagents and custom development services based near St. Louis, Missouri. The growth equity investment will fund expanded manufacturing capacity, broaden scientific capabilities and product offerings, and support Leinco's commercial and geographic expansion while leadership including founder Pat Leinert Sr. remain involved.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Alliance Pharma (Ampersand-backed) Acquires LGC's Drug Development Solutions; KKR Joins as Equal Shareholder

May 17, 2022

Healthcare Services

Alliance Pharma, an Ampersand-backed US bioanalytical CRO, acquired Drug Development Solutions (DDS), LGC’s UK-based bioanalytical and materials science testing business. Ampersand Capital Partners and KKR will be equal shareholders in the combined business to expand geographic reach, broaden laboratory capabilities, and extend the service portfolio internationally.

Heritage Global Partners Acquires American Laboratory Trading

August 23, 2021

Industrial Services

Heritage Global Partners (an affiliate of Heritage Global Inc.) acquired substantially all of the assets of American Laboratory Trading (ALT), a leading North American reseller of refurbished laboratory equipment. The deal includes ALT's building in East Lyme, Connecticut, and is intended to expand HGP's biotech and pharma services and New England footprint.